Developer docs
API playgroundTry for free, no card

Search company profiles

BrainStorm Therapeutics

Full company profile

uuid0296fae

Namestring
BrainStorm Therapeutics
Legal namestring
BrainStorm Therapeutics, Inc.
Company typeenum
Private
Founded yearint
2020
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CNS drug discovery, brain organoid platform, AI drug discovery, iPSC disease models, neurological therapeutics
Industry4 codes
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
CNS Drug Discovery
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Foundation Grants
TypeGrants Donations
Description

LouLou Foundation grant supporting the Parkinson's and rare epilepsy AI discovery collaboration between BioSymetrics and BrainStorm Therapeutics.

biospace.com
2Government Defense Contracts
TypeOthers
Description

Revenue-generating multi-year defense collaboration secured through BioSymetrics for AI-enabled chemical threat assessment with the U.S. government. Referenced in Lunai Bioworks shareholder letter as a revenue-generating contract.

aijourn.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

BrainStorm Therapeutics operates a drug discovery platform that combines patient-derived iPSC brain organoid disease models with deep learning, network medicine, and foundation models (e.g., NVIDIA BioNeMo Geneformer) to identify, validate, and de-risk therapeutic targets and candidates for CNS and rare neurological disorders. The platform enables high-throughput screening of thousands of drug molecules per day on human brain cells and is designed to produce development-ready neurology programs for pharmaceutical partnering, licensing, and downstream development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Screened thousands of drug molecules per day directly on human brain cells
+2 more records
Product overview1 text field

BrainStorm Therapeutics offers a unified AI-powered drug discovery platform centered on human patient iPSC-derived brain organoid technology. The platform integrates advanced computational tools including deep learning and network medicine with living 3D brain organoid models to discover and develop therapeutic candidates for neurological disorders. The platform enables high-throughput screening of thousands of drug molecules per day using clinically translatable disease endpoints, with a current focus on Parkinson's disease, rare genetic epilepsies, and neurodevelopmental disorders like Rett syndrome and CDKL5 deficiency disorder. Through collaborations with partners like BioSymetrics (Lunai Bioworks), the company generates development-ready neurology programs designed for pharmaceutical partnering and downstream development.

Product and service2 records
1Brain Organoid Drug Discovery Platform
Categorycore product
Description

Proprietary AI-powered platform combining human patient iPSC-derived brain organoid disease models with deep learning and network medicine to identify therapeutic candidates that halt, prevent, or reverse synaptic network dysfunction and neurodegeneration for complex neurological disorders. Designed for pharmaceutical partnering and licensing.

2Foundation Model-Based Organoid Network Browser
Categorydata analytics tool
Description

Proprietary multimodal data infrastructure and browser for exploring organoid network data, integrating cell sequencing, imaging, and EEG-like brain wave data from organoid experiments.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-29
Description

BioSymetrics (wholly owned subsidiary of Lunai Bioworks) and BrainStorm Therapeutics launched a foundation-funded strategic collaboration to jointly discover and advance novel therapeutic targets for Parkinson's disease and rare genetic epilepsies. The partnership combines BioSymetrics' AI-driven target discovery and in vivo zebrafish validation platform with BrainStorm's human-derived organoid systems, initially focusing on rare genetic epilepsies and Parkinson's disease. Supported by a LouLou Foundation grant.

Strategic tierCoreTypeTechnology or Integration
Description

BrainStorm's AI models run on NVIDIA GPUs in the cloud using the NVIDIA BioNeMo Framework. The company is a member of NVIDIA Inception, a global network of cutting-edge startups. BrainStorm used Geneformer model available through BioNeMo for gene expression analysis and is collaborating with the NVIDIA BioNeMo team to optimize open-source access to Geneformer.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

BrainStorm's next major project is an initiative with the CURE5 Foundation to conduct the most comprehensive repurposed drug screen to date for CDKL5 Deficiency Disorder, a rare genetic neurodevelopmental disorder.

4Dr. Alysson Muotri (UCSD)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Dr. Alysson Muotri, professor at UCSD and creator of the first human organoid models for neurodevelopmental disorders, serves on the company's Scientific Advisory Board. He directs the Stem Cell Program and Archealization Center at UCSD and is co-director of the new Gene Therapy Initiative.

brainstormtherapeutics.org
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Molecular Devices provides high-content imaging and FLIPR-style screening instruments used in organoid-based drug screening. BrainStorm uses FLIPR-based imaging, making Molecular Devices an enabling infrastructure peer in the workflow.

TypeDirect peer
Description

Newcells Biotech offers iPSC-derived organoid models, including neural organoids, for drug discovery and toxicity testing. It is a comparable organoid-platform peer serving pharma R&D clients.

TypeBroad incumbent
Description

Recursion is a leading AI-driven drug discovery company combining high-throughput biology with machine learning, with established multi-program pharma partnerships (Roche, Genentech, Bayer). It represents a much larger-scale competitor in the AI-discovery space.

TypeDirect peer
Description

Insitro combines machine learning with high-throughput biology (including iPSC-derived disease models) for drug discovery. It targets pharma partnerships in CNS and metabolic disease, directly overlapping with BrainStorm's AI-driven CNS drug discovery thesis.

TypeDirect peer
Description

Verge Genomics applies AI/ML to human CNS disease data to identify novel therapeutic targets, with partnerships in ALS and Parkinson's. It is a direct AI-CNS-discovery competitor pursuing pharma licensing deals.

TypeEmerging player
Description

CAMP4 Therapeutics applies regulatory RNA biology to CNS disorders, and Robert Fremeau previously served as Executive Director there. It represents an adjacent CNS platform peer with overlapping leadership pedigree and target-validation focus.

TypeBroad incumbent
Description

FUJIFILM Cellular Dynamics is a leading provider of iPSC-derived cells and neural disease models for drug discovery. Blake Anson, BrainStorm's business development lead, was previously Senior Director there, and the company's iPSC-derived CNS models directly overlap with BrainStorm's organoid offerings.

TypeDirect peer
Description

StemoniX pioneered iPSC-derived brain organoids for drug discovery and is now part of Vyant Bio, where BrainStorm CEO Robert Fremeau previously served as CSO. It is the most direct functional peer given shared organoid platform technology and overlapping pharma customer base.

TypeBroad incumbent
Description

Charles River is a major preclinical CRO offering iPSC-derived cell and organoid services for CNS drug discovery. It competes with BrainStorm for pharma preclinical partnership business and offers broader integrated services.

TypeDirect peer
Description

bit.bio develops iPSC-derived human cell types including neural cells for drug discovery and disease modeling. It competes with BrainStorm in providing consistent, scalable human neural models for pharma screening programs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BrainStorm Therapeutics

CNS Drug Discoverybrainstormtherapeutics.org

BrainStorm Therapeutics firmographics

Firmographics
Name
BrainStorm Therapeutics
Legal name
BrainStorm Therapeutics, Inc.
Website
https://brainstormtherapeutics.org
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

BrainStorm Therapeutics industry classification

Industry
Product category
CNS Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • CNS drug discovery
  • Brain organoid platform
  • AI drug discovery
  • IPSC disease models
  • Neurological therapeutics

Where BrainStorm Therapeutics is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

BrainStorm Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Foundation Grants: LouLou Foundation grant supporting the Parkinson's and rare epilepsy AI discovery collaboration between BioSymetrics and BrainStorm Therapeutics.
  2. Government Defense Contracts: Revenue-generating multi-year defense collaboration secured through BioSymetrics for AI-enabled chemical threat assessment with the U.S. government. Referenced in Lunai Bioworks shareholder letter as a revenue-generating contract.

Go-to-market motion3 records

Distribution channels1 record

Marketing channels5 records

BrainStorm Therapeutics product offering

Product offering

Core offering

BrainStorm Therapeutics operates a drug discovery platform that combines patient-derived iPSC brain organoid disease models with deep learning, network medicine, and foundation models (e.g., NVIDIA BioNeMo Geneformer) to identify, validate, and de-risk therapeutic targets and candidates for CNS and rare neurological disorders. The platform enables high-throughput screening of thousands of drug molecules per day on human brain cells and is designed to produce development-ready neurology programs for pharmaceutical partnering, licensing, and downstream development.

Product overview

BrainStorm Therapeutics offers a unified AI-powered drug discovery platform centered on human patient iPSC-derived brain organoid technology. The platform integrates advanced computational tools including deep learning and network medicine with living 3D brain organoid models to discover and develop therapeutic candidates for neurological disorders. The platform enables high-throughput screening of thousands of drug molecules per day using clinically translatable disease endpoints, with a current focus on Parkinson's disease, rare genetic epilepsies, and neurodevelopmental disorders like Rett syndrome and CDKL5 deficiency disorder. Through collaborations with partners like BioSymetrics (Lunai Bioworks), the company generates development-ready neurology programs designed for pharmaceutical partnering and downstream development.

Differentiator

Problem solved

Functional benefit

Products and services

  • Brain Organoid Drug Discovery Platform Proprietary AI-powered platform combining human patient iPSC-derived brain organoid disease models with deep learning and network medicine to identify therapeutic candidates that halt, prevent, or reverse synaptic network dysfunction and neurodegeneration for complex neurological disorders. Designed for pharmaceutical partnering and licensing.
  • Foundation Model-Based Organoid Network Browser Proprietary multimodal data infrastructure and browser for exploring organoid network data, integrating cell sequencing, imaging, and EEG-like brain wave data from organoid experiments.

Quantifiable outcome

  • Screened thousands of drug molecules per day directly on human brain cells
  • +2 more outcomes

Companies that use BrainStorm Therapeutics

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

BrainStorm Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature6 records

BrainStorm Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and major.

  • Lunai Bioworks (BioSymetrics)coreStrategic or Co-development Partner · 29 May 2026BioSymetrics (wholly owned subsidiary of Lunai Bioworks) and BrainStorm Therapeutics launched a foundation-funded strategic collaboration to jointly discover and advance novel therapeutic targets for Parkinson's disease and rare genetic epilepsies. The partnership combines BioSymetrics' AI-driven target discovery and in vivo zebrafish validation platform with BrainStorm's human-derived organoid systems, initially focusing on rare genetic epilepsies and Parkinson's disease. Supported by a LouLou Foundation grant.
  • NVIDIAcoreTechnology or IntegrationBrainStorm's AI models run on NVIDIA GPUs in the cloud using the NVIDIA BioNeMo Framework. The company is a member of NVIDIA Inception, a global network of cutting-edge startups. BrainStorm used Geneformer model available through BioNeMo for gene expression analysis and is collaborating with the NVIDIA BioNeMo team to optimize open-source access to Geneformer.
  • CURE5 FoundationmajorStrategic or Co-development PartnerBrainStorm's next major project is an initiative with the CURE5 Foundation to conduct the most comprehensive repurposed drug screen to date for CDKL5 Deficiency Disorder, a rare genetic neurodevelopmental disorder.
  • Dr. Alysson Muotri (UCSD)coreStrategic or Co-development PartnerDr. Alysson Muotri, professor at UCSD and creator of the first human organoid models for neurodevelopmental disorders, serves on the company's Scientific Advisory Board. He directs the Stem Cell Program and Archealization Center at UCSD and is co-director of the new Gene Therapy Initiative.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

BrainStorm Therapeutics competitors and assessment

Company assessment

Others

  • Molecular Devices: Molecular Devices provides high-content imaging and FLIPR-style screening instruments used in organoid-based drug screening. BrainStorm uses FLIPR-based imaging, making Molecular Devices an enabling infrastructure peer in the workflow.

Direct peers

  • Newcells Biotech: Newcells Biotech offers iPSC-derived organoid models, including neural organoids, for drug discovery and toxicity testing. It is a comparable organoid-platform peer serving pharma R&D clients.
  • Insitro: Insitro combines machine learning with high-throughput biology (including iPSC-derived disease models) for drug discovery. It targets pharma partnerships in CNS and metabolic disease, directly overlapping with BrainStorm's AI-driven CNS drug discovery thesis.
  • Verge Genomics: Verge Genomics applies AI/ML to human CNS disease data to identify novel therapeutic targets, with partnerships in ALS and Parkinson's. It is a direct AI-CNS-discovery competitor pursuing pharma licensing deals.
  • StemoniX (Vyant Bio): StemoniX pioneered iPSC-derived brain organoids for drug discovery and is now part of Vyant Bio, where BrainStorm CEO Robert Fremeau previously served as CSO. It is the most direct functional peer given shared organoid platform technology and overlapping pharma customer base.
  • bit.bio: bit.bio develops iPSC-derived human cell types including neural cells for drug discovery and disease modeling. It competes with BrainStorm in providing consistent, scalable human neural models for pharma screening programs.

Broad incumbents

  • Recursion Pharmaceuticals: Recursion is a leading AI-driven drug discovery company combining high-throughput biology with machine learning, with established multi-program pharma partnerships (Roche, Genentech, Bayer). It represents a much larger-scale competitor in the AI-discovery space.
  • FUJIFILM Cellular Dynamics: FUJIFILM Cellular Dynamics is a leading provider of iPSC-derived cells and neural disease models for drug discovery. Blake Anson, BrainStorm's business development lead, was previously Senior Director there, and the company's iPSC-derived CNS models directly overlap with BrainStorm's organoid offerings.
  • Charles River Laboratories: Charles River is a major preclinical CRO offering iPSC-derived cell and organoid services for CNS drug discovery. It competes with BrainStorm for pharma preclinical partnership business and offers broader integrated services.

Emerging players

  • CAMP4 Therapeutics: CAMP4 Therapeutics applies regulatory RNA biology to CNS disorders, and Robert Fremeau previously served as Executive Director there. It represents an adjacent CNS platform peer with overlapping leadership pedigree and target-validation focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

BrainStorm Therapeutics social profiles

Digital presence

BrainStorm Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BrainStorm Therapeutics leadership team

Management profile

Number of profiles

Profiles7 records

BrainStorm Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BrainStorm Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BrainStorm Therapeutics

What does BrainStorm Therapeutics do?

BrainStorm Therapeutics operates a drug discovery platform that combines patient-derived iPSC brain organoid disease models with deep learning, network medicine, and foundation models (e.g., NVIDIA BioNeMo Geneformer) to identify, validate, and de-risk therapeutic targets and candidates for CNS and rare neurological disorders. The platform enables high-throughput screening of thousands of drug molecules per day on human brain cells and is designed to produce development-ready neurology programs for pharmaceutical partnering, licensing, and downstream development.

Is BrainStorm Therapeutics a public or private company?

BrainStorm Therapeutics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was BrainStorm Therapeutics founded?

BrainStorm Therapeutics was founded in 2020. It employs 1 to 10 people.

Where is BrainStorm Therapeutics based?

BrainStorm Therapeutics is headquartered in San Diego, United States, in the North America region.

How does BrainStorm Therapeutics make money?

Two revenue lines are on record. Foundation Grants are the primary driver. The others are government Defense Contracts.

Who are BrainStorm Therapeutics's main competitors?

Molecular Devices is listed as an others. Direct peers are Newcells Biotech, Insitro, Verge Genomics, StemoniX (Vyant Bio) and bit.bio. Broad incumbents are Recursion Pharmaceuticals, FUJIFILM Cellular Dynamics and Charles River Laboratories. CAMP4 Therapeutics is listed as an emerging player.

Does BrainStorm Therapeutics have an API?

No public API is recorded for BrainStorm Therapeutics.

What industry is BrainStorm Therapeutics in?

BrainStorm Therapeutics's product category is CNS Drug Discovery. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageLunai Bioworks (N A S D A Q: LNAI) Takes Parkinson's Discovery to the Next Level With Exclusive Tanaist AgreementLunai Bioworks announced an exclusive worldwide license with Tanaist to add human cellular phenotyping to its Parkinson's discovery platform. The agreement aims to validate three AI-identified patient subtypes, potentially enabling biomarker and therapeutic-target development. The company also has a BrainStorm collaboration with a first-half 2027 data readout.AijournLunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson’s Disease Data Readout Targeted for First Half of 2027Lunai Bioworks Inc. (Nasdaq: LNAI) has executed a Master Collaboration Agreement with BrainStorm Therapeutics Inc. to develop an integrated AI-driven workflow for Parkinson's disease research, combining BioSymetrics' patient-stratification platform with BrainStorm's human midbrain organoid technology. The collaboration targets an initial data readout in the first half of 2027 and follows the publication of a BioSymetrics white paper on Parkinson’s disease subtypes derived from the PPMI dataset. The agreement establishes a three-stage commercial strategy spanning clinical-trial enrichment for pharma partners, biomarker panel development, and partner-ready therapeutic programs using validated human biological systems.AInvestLunai Bioworks (NASDAQ: LNAI) signs definitive collaboration agreement with Brainstorm Therapeutics; initial Parkinson's disease data readout targeted for first half of 2027Lunai Bioworks has signed a definitive collaboration agreement with Brainstorm Therapeutics to advance Parkinson's disease research, integrating AI-driven discovery, human brain organoid modeling, and in vivo validation capabilities. The partnership combines Brainstorm Therapeutics' organoid systems with Lunai Bioworks' Augusta Platform and BioSymetrics' AI target discovery tools, initially focusing on Parkinson's disease and rare genetic epilepsies, with the goal of identifying biomarkers and therapeutic targets for pharmaceutical partnering. A key milestone is the anticipated first data readout in the first half of 2027, while the Parkinson's disease market is projected to grow from $6-8 billion currently to over $13 billion by the 2030s.YahooLunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027Lunai Bioworks signed a collaboration agreement with BrainStorm Therapeutics to develop Parkinson's disease therapies, with initial data expected in the first half of 2027. The collaboration combines AI-driven patient stratification and human brain organoid research to identify disease subtypes, biomarkers, and therapeutic targets.Stock TitanLunai Bioworks Signs Parkinson’s Collaboration; 2027 DataLunai Bioworks Inc. (Nasdaq: LNAI) has signed a Master Collaboration Agreement with BrainStorm Therapeutics Inc. to jointly advance Parkinson's disease research, combining BioSymetrics' AI-powered patient-stratification platform with BrainStorm's patient-derived human midbrain organoid technology. The collaboration targets an initial data readout in the first half of 2027 and follows BioSymetrics' publication of a technical white paper identifying clinically distinct Parkinson's disease subtypes from the PPMI dataset. The partnership has a three-stage commercial strategy encompassing clinical-trial design support, biomarker panel development, and generation of partner-ready therapeutic programs for pharmaceutical collaborators.PR NewswireLunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027Lunai Bioworks and BrainStorm Therapeutics executed a Master Collaboration Agreement and published a white paper on Parkinson's disease subtypes. The collaboration targets an initial data readout in the first half of 2027, combining BioSymetrics' AI stratification with BrainStorm's organoid platform. The companies aim to develop biomarker panels and partner-ready therapeutic programs.BioSpaceLunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson’s and Rare Epilepsy AI Discovery CollaborationLunai Bioworks' wholly owned subsidiary BioSymetrics and BrainStorm Therapeutics announced a strategic collaboration and Letter of Intent to jointly discover, validate, and advance novel therapeutic targets for neurological diseases including Parkinson's disease and rare genetic epilepsies, supported by a newly awarded grant from the LouLou Foundation. The collaboration integrates BioSymetrics' AI-driven target discovery and in vivo zebrafish validation platform with BrainStorm's proprietary human-derived organoid systems, aligning with emerging FDA guidance on new approach methodologies. The companies aim to generate high-confidence, development-ready neurology programs designed for pharmaceutical partnering, licensing, and downstream co-development structures.SdbnLunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson’s and Rare Epilepsy AI Discovery Collaboration – San Diego Biotechnology NetworkLunai Bioworks and BrainStorm Therapeutics announced a foundation-funded collaboration focused on AI-driven drug discovery for Parkinson's disease and rare epilepsy, integrating human brain organoid modeling with in vivo validation. The partnership aims to generate differentiated neurology assets for pharmaceutical partnering and development. Both companies will leverage their respective capabilities in AI discovery and biotech research under this initiative.LunaibioworksLunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery CollaborationLunai Bioworks and BrainStorm Therapeutics announced a collaboration to discover and validate therapeutic targets for Parkinson's disease and rare epilepsies, supported by a LouLou Foundation grant. The partnership combines AI-driven discovery, organoid modeling, and zebrafish validation, aiming to generate development-ready neurology programs for pharmaceutical partnering.EIN PresswireLunai Bioworks & BrainStorm Therapeutics Launch Foundation-Funded Parkinson’s & Rare Epilepsy AI Discovery CollaborationLunai Bioworks and BrainStorm Therapeutics announced a collaboration and Letter of Intent to jointly discover and validate therapeutic targets for neurological diseases, supported by a LouLou Foundation grant. The partnership combines AI-driven discovery, human organoid systems, and in vivo zebrafish validation, with initial focus on rare epilepsies and Parkinson's disease. The companies aim to generate development-ready programs for pharmaceutical partnering and licensing.